Background Lopinavir (LPV)/ritonavir (RTV) co-formulation (LPV/RTV) is a widely used protease inhibitor (PI)-based regimen to treat HIV-infection. As with all PIs, the trough concentration (C trough ) is a primary determinant of response, but the optimum exposure remains poorly defined. The primary objective was to develop an integrated LPV population pharmacokinetic model to investigate the influence of a-1-acid glycoprotein and link total and free LPV exposure to pharmacodynamic changes in HIV-1 RNA and assess viral dynamic and drug efficacy parameters. Methods Data from 35 treatment-naïve HIV-infected patients initiating therapy with LPV/RTV 400/100 mg orally twice daily across two studies were used for model development and simulations using ADAPT. Total LPV (LPV t ) and RTV concentrations were measured by highperformance liquid chromatography with ultraviolet (UV) detection. Free LPV (LPV f ) concentrations were measured using equilibrium dialysis and mass spectrometry. Results The LPV t typical value of clearance (CL LPV t =F) was 4.73 L/h and the distribution volume (V LPV t =F) was 55.7 L. The clearance (CL LPV f =F) and distribution volume (V f /F) for LPV f were 596 L/h and 6,370 L, respectively. The virion clearance rate was 0.0350 h -1 . The simulated LPV LPV t C trough values at 90 % (EC 90 ) and 95 % (EC 95 ) of the maximum response were 316 and 726 ng/mL, respectively.
Introduction
Over the past several years, it has become evident that achieving and maintaining adequate antiretroviral (ARV) concentrations is required to produce a sustained virological response. It is also well recognized that the durability of an ARV regimen is limited not only by inadequate drug exposure and subsequent development of viral resistance, but also by the occurrence of toxicities often related to long-term exposure to higher plasma and tissue drug concentrations [1] .
Protease inhibitors (PIs) are bound with high affinity primarily to a-1-acid glycoprotein (AAG), thus free plasma concentrations are inversely related to AAG concentrations. As an acute-phase protein, AAG synthesis rises significantly in response to acute and chronic inflammation such as that encountered with infections and injuries [2] , a factor that may account for the observed variability in plasma AAG concentrations with chronic HIV infection. Given the PIs high binding affinity for AAG, their high plasma concentrations in the presence of ritonavir (RTV) and the low saturation capacity of AAG, it has been speculated that variations in AAG levels could result in clinically important changes in PI pharmacokinetics and pharmacodynamics. Since a free drug's concentration more accurately reflect its availability to target cells, changes in AAG concentrations could have important clinical implications. However, the inverse relationship between free drug and binding protein concentrations is likely an oversimplification of their dynamics. Under normal physiological conditions, plasma protein binding has little or no effect on the free concentrations of many drugs. This is because at steady state, equilibrium is maintained between free drug concentrations and plasma drug clearance such that the elimination rate is increased as free concentrations increase, and vice versa [3] . For certain drugs, alterations in protein binding can lead to clinically significant changes in pharmacokinetics and pharmacodynamics [4] .
Lopinavir (LPV) is an inhibitor of the HIV-1 protease. LPV, co-formulated with low-dose RTV [Kaletra (LPV/ RTV, 400/100 mg)], is a frequently used PI regimen for the treatment of HIV infection because of its high effectiveness and reasonable tolerability. LPV is primarily metabolized by cytochrome P450 3A4 (CYP3A4), but co-administration with low-dose RTV, a potent inhibitor of CYP3A4, significantly increases LPV plasma concentrations [5] . The in vitro half-maximal inhibitory concentration (IC 50 ) of LPV is approximately tenfold lower than that of RTV, and RTV systemic exposure is low following a 100 mg dose [6] . Thus the antiviral activity of LPV/RTV is due primarily to LPV [6, 7] . A mechanistic understanding of the complex interplay between free concentrations, CYP3A4 inhibition, plasma protein binding, antiviral efficacy and development of viral resistance will lead to more informed dosing strategies with currently approved ARVs and those in development.
Establishing ARV concentrations that exceed the susceptibility of the virus is required for robust suppression of viral replication. PI trough concentration (C trough ) values are correlated with response, but determination of target C trough values is hindered by a dearth of in vivo concentration-response data typically determined during early-phase drug development. Without in vivo concentration-response data, protein binding-adjusted in vitro susceptibility measurements may provide surrogate estimates of the optimal in vivo C trough . To date, population models directly linking free PI concentrations to drug response in vivo are lacking. To address this limitation, we developed an integrated population model to describe the influence of AAG on the equilibrium of total and free plasma LPV concentrations, including the effect of RTV exposure and other relevant covariates. The integrated model also links free LPV concentrations to HIV-1 viral dynamics, which allows an assessment of the role of clinically relevant changes in LPV binding in changes in the plasma viral load in treatment-naïve HIV-infected individuals with predominantly wild-type virus.
Subjects and Methods

Subjects and Study Design
Data from two studies in treatment-naïve HIV-infected patients initiating ARV therapy were used for these analyses. Both studies were conducted at a single centre and were prospective, multiple-dose intensive single and/or steadystate pharmacokinetic studies in which subjects were recruited from the Grady Infectious Diseases Program (IDP) outpatient clinic in Atlanta, GA, USA. Eligibility included male and female subjects aged C18 years with HIV-1 RNA polymerase chain reaction (PCR) C50,000 copies/mL. Subjects were not enrolled if they were on medications that could interact with the PIs or were on investigational ARV agents, had an active opportunistic infection, had renal/ hepatic impairment or were pregnant. At enrollment, demographic information and clinical laboratory data were collected, and ARV adherence counselling was provided to all subjects. Subjects initiated therapy with LPV/RTV 400/100 mg orally twice daily plus standard dosing of two nucleoside reverse transcriptase inhibitors. All subjects provided written informed consent before undergoing any study procedures. These trials were designed according to the ethical guidelines for human studies and approved by the Emory University Institutional Review Board.
Plasma AAG concentrations were quantified using an enzyme-linked immunosorbent assay (ELISA). Total LPV (LPV t ) and RTV were measured by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection [8] . Free LPV (LPV f ) was quantitated using equilibrium dialysis followed by mass spectrometry (MS). A reversed-phase HPLC assay, coupled to a triple quadrupole mass spectrometer (MS/MS) for detection, was developed and validated for the determination of free LPV in human plasma (range 0.25-80 ng/mL). Sample preparation involved equilibrium dialysis, the addition of a labelled isotope internal standard (IS; Lopinavir d-8) and a simple protein precipitation method using acetonitrile. The sample was dried down and reconstituted in 100 lL of 50/50 acetonitrile/water to concentrate the sample. Reversed-phase chromatographic separation of LPV and IS was performed on an Atlantis Ò dC18 2.1 9 100 mm column under isocratic conditions. A binary mobile phase was used consisting of 20 % 0.1 % formic acid in water and 80 % 0.1 % formic acid in acetonitrile. The detection and quantitation was achieved for LPV and IS by multiple reaction monitoring (MRM). The de-protonated molecular ions [M-H] -were monitored at m/z 629.5 ? 447.1 for LPV and 637.5 ? 447.2 for IS. These provided adequate sensitivity with minimal interference from endogenous matrix components.
In study 1 (S1), 16 patients underwent intensive plasma sampling (at 1, 2, 3, 4, 6, 8, 10 and 12 h post-dose) at 2 and 16 weeks post-treatment initiation. The study population, design and enrollment criteria have been previously reported [9] . In study 2 (S2), 20 patients underwent plasma sampling (at -2, 0, 1, 2, 3 and 4 h) on day 1 (second dose) and at weeks 2 and 24. In S2, intensive HIV-1 RNA sampling was also performed. Pre-dose (time 0) AAG and HIV-1 RNA samples were obtained and the first dose of an LPV/RTV-based ARV regimen was administered during a 48-h clinic visit. All S2 participants also received tenofovir disoproxil fumarate and emtricitabine. Thirty-six subjects from both studies were available for population pharmacokinetic analysis, and 20 of the S2 subjects had intensive HIV-1 RNA sampling. Thirty-five subjects were used for pharmacokinetic analysis: one subject with very low LPV concentrations (suggesting poor adherence) was excluded. Nineteen subjects from S2 were used for pharmacokinetic-pharmacodynamic analyses. One subject with ten viral load measurements above the limit of quantitation was removed. Five viral load measurements from three different subjects were excluded because of likely problems with adherence.
Mathematical Modelling
The population model was developed sequentially by first creating a joint model for LPV t and RTV, followed by an independent model relating AAG and LPV t with LPV f . A viral dynamic model was then developed simultaneously with CD4 cell count results and integrated with the submodels to construct the composite final pharmacokineticpharmacodynamic model depicted in Fig. 1 . As indicated in Fig. 1 , LPV t CL LPV t =F depends on the concentration of ritonavir (C RTV ), where the LPV f concentration (C LPV f ) is a function of both LPV t (C LPV t ) and AAG. The LPV effect on viral dynamics was modelled by linking C LPV f through transit delay compartments.
Population analysis was used to develop each of the four components of the overall pharmacokinetic-pharmacodynamic model. Maximum likelihood estimates for model parameters were obtained through the application of the expectation maximization algorithm to the parametric, nonlinear mixed-effects maximum likelihood model, as proposed and developed by Schumitzky [10] and Walker [11] and implemented in ADAPT (version 5, MLEM module) [12] . Model parameters were assumed to follow a delay compartments, I infected CD4? T-cells, k aLPVt absorption rate constant of LPV t , k aRTV absorption rate constant of RTV, LPV f free lopinavir, LPV t total lopinavir, N number of new virions produced by each infected CD4? T-cell during its lifetime, PK pharmacokinetics, RTV ritonavir, T CD4? T-cells, T lag,t absorption lag time of LPV t , T lag,r RTV absorption lag time, v free virions, V LPVt volume of distribution of the LPV t central compartment, V RTV volume of distribution of the RTV central compartment multivariate log-normal distribution, with stage 1 random error taken to be normally distributed with a proportional plus additive error variance.
The following covariates collected at baseline were evaluated for their ability to explain the inter-individual variability (IIV) in base model parameters: sex, age, race, weight, height, body mass index (BMI), serum creatinine, creatinine clearance and the hepatic enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT). The criterion for a covariate to be added to the final model was a decrease of more than 3.84 in the minus two log likelihood value (-2 LL), which corresponds to a P value of 0.05 (log likelihood ratio test). Finally, a stepwise backward elimination was carried out. The criteria for a covariate to remain in the final model was P \ 0.01, corresponding to a decrease of 6.63 in the -2 LL.
Model evaluation was assessed using a prediction-corrected visual predictive check (pcVPC) [13] with NON-MEM (version VII), Perl speaks NONMEM (PsN, version 3.4.2) [14] and Xpose (version 4.4.0) [15] (1,000 data sets were simulated). The 95 % confidence intervals of the median and the 5th and 95th percentiles of the simulated concentrations at different times were calculated and compared with the prediction corrected observations.
Pharmacokinetic Models
Data from S1 and S2 were used for population modelling of LPV t and RTV. Initially, separate models for LPV t and RTV were established by considering one-and two-compartment models with and without an absorption lag phase (model selection based on the likelihood ratio test). Next, a joint model of LPV t and RTV (LPV t /RTV) was developed using LPV t and RTV measurements simultaneously by examining various models to represent the relationship between RTV concentrations and LPV t clearance [16] . The following equations (1-4) represent the joint model for both drugs, including an exponential term for the effect of RTV concentration on LPV t clearance:
In the above equations, A1 and A2 are the amount of LPV t in the measured (central) and absorption compartments, respectively, while A3 and A4 represent the amounts of RTV in the measured and absorption compartments, respectively (all amounts are in mg). In Eq.
(1), CL LPV t0 (L/h) is the typical LPV t clearance and is used to explain the effect of RTV (C RTV , which equals A3/V RTV in mg/L) on LPV t clearance. The value 299 in Eq. 1 is the median RTV concentration in ng/mL and c 1 is the RTV effect coefficient. CL RTV (L/h) is the clearance of RTV, while V LPV t (L) and V RTV (L) are the distribution volumes of LPV t and RTV, and k aLPV t (h -1 ) and k aRTV (h -1 ) are the LPV t and RTV absorption rate constants. Throughout the model, CL and V terms represent apparent clearance and volume (CL/F and V/F) for LPV t and RTV as well as LPV f .
AAG-Dependent LPV f Model
The model relating both LPV f and LPV t to AAG assumes that LPV f is in rapid equilibrium with LPV t . A separate population analysis relating measured LPV t and AAG concentrations (model inputs) to LPV f concentrations (observations) was conducted using the pooled data from S1 and S2, and the following model was selected based on previously reported data [17] :
where fu 0 is the fraction of unbound LPV at the median AAG (91.8 mg/dL) and p 1 is the slope for AAG.
HIV-1 Viral Dynamic Model
To describe the measured plasma HIV-1 RNA concentrations and the CD4? T-cell counts obtained in S2, we adopted, with a slight modification, the following previously reported model [18, 19] , representing HIV and immune system dynamics during antiviral treatment.
These three differential equations represent target CD4? T-cells (T, cells/lL), infected CD4? T-cells (I, cells/lL) and free virions (v, copies/mL). The measured CD4 count data is the combined total of states T and I. To account for the delay between the initiation of therapy and the observed decrease in viral load, mainly attributed to the time required for the completion of the viral replication cycle in productively infected cells [20] , several transit delay compartments were used to link C LPV f to the efficacy term e. The transduction delay model is as follows:
where D1 and D2 are the signals in the delay compartments, I max is the maximum inhibition effect of LPV f (fixed at 1 assuming no escaping virus routes), IC 50 is the concentration at half I max , c is the hill coefficient, s (h) is the mean transit time for each compartment and C LPV f is the predicted LPV f concentration. The latter was determined for each patient via a separate population analysis (one-compartment model with lag time) using measured LPV f concentrations. For model building, 2, 3 and 4 transit delay compartments were evaluated. It was assumed that only LPV, not RTV, acts on the virus since the in vitro antiviral IC 50 of LPV is approximately tenfold lower than that of ritonavir [6] . It was further assumed that the viral dynamics are at steady state prior to the initiation of therapy, at least relative to the time course of drug action, and therefore the following relationships can be derived from Eqs. (6-8)
where T 0 , I 0 and v 0 are the initial value of target CD4? T-cells, infected CD4? T-cells and viral load, respectively.
Exposure-Response Simulations
Simulation studies were conducted to explore exposureresponse relationships using the LPV f , AAG-dependent LPV f and viral dynamic models. Simulated LPV doses ranged from 5 to 700 mg twice daily (18 different doses). The pharmacodynamic determinant of response was the decrease in the log 10 time-averaged area under the viral load-time curve from 0 to 7 days (AUC 0-7days ) minus baseline (AAUCMB) [21, 22] of HIV-1 RNA. The AAUCMB was determined for each patient using their estimated population mean values of the viral dynamic model and AAUCMB was used to determine the average viral load decrease over the first 7 days of treatment. The goal of these simulations was to link the LPV f 12 h steadystate concentrations (C f12h ) to changes in AAUCMB and determine the corresponding LPV t 12 h steady-state concentration (C t12h ) required to produce 50 % (EC 50 ), 90 % (EC 90 ) and 95 % (EC 95 ) of the maximum drug effect (E max ). The exposure-response relationship of C f12h and the decrease in AAUCMB was fitted using the following E max model:
where E max is the maximum response, EC 50 is C f12h that corresponds to 50 % of E max and c, the hill coefficient, describes the shape of the sigmoid curve. The C f12h EC 90 and EC 95 values were calculated from Eq. (13) using the estimated values of EC 50 and c. The corresponding EC 95 for C t12h was calculated using the AAG-dependent LPV f model (Eq. 5), for the median and range of C f12h and AAG measurements in this study.
Results
Demographic and Baseline Data
Of the 35 subjects included in the pharmacokinetic modelling analysis, 25 were male and 10 were female, and 31 were African American and 4 were Caucasian. where CL LPV t1 is typical clearance at median BMI (22.5 kg/m 2 ) and CL LPV t2 is the coefficient of BMI effect. The population parameter estimates of the combined LPV t / RTV model are shown in Table 2 (BMI was not a significant covariate in the RTV analysis). The absorption rate constant (k aLPV t ) and lag time (T lag,t ) for LPV t were both fixed to their individual conditional mean values from the separate LPV t modelling in developing the integrated LPV t /RTV model. An exponential term was used to incorporate the effect of RTV concentration on the clearance of LPV t (see Eq. 1). At the median values of BMI (22.5 kg/m 2 ) and plasma RTV concentration (299 ng/mL), the model predicts LPV t CL to be 4.73 (L/h). Figure 2 displays the individual prediction goodness-of-fit plots of LPV t and LPV f concentrations for the combined LPV t / RTV model. The population prediction goodness-of-fit plots are presented in Supplementary Fig. 2 in the Electronic Supplementary Material. The pcVPCs for LPV t and LPV f are shown in Fig. 3 , which represent the combination of week 2 and week 16 for S1, and week 2 and week 24 for S2.
AAG-Dependent LPV f Model
The LPV t and LPV f plasma concentration data from S1 and S2 were pooled, along with the associated AAG measurements, and a separate population analysis using Eq. (5) resulted in model parameter estimates shown in Table 2 (goodness-of-fit plots are presented in Supplementary  Fig. 3 in the Electronic Supplementary Material).
Simulated fu as a function of AAG for each individual were was also performed. The individual predictions over the AAG range measured in each subject are shown in Supplementary Fig. 4 in the Electronic Supplementary Material. The AAG-dependent LPV f model found that over the range of AAG values in the two studies (23.6-479 mg/dL) there is a significant effect of AAG on binding with fu values ranging from 0.00903 to 0.00389, which is consistent with prior protein-free LPV studies [23] . Table 2 lists the viral dynamic parameters derived using individual conditional mean values obtained from the LPV f and viral dynamic models from Eqs. (6) (7) (8) (9) (10) (11) . In this analysis, d and delta could not be simultaneously estimated because CD4 cell count data were modelled using the combined total of states T and I. As a result, the death rate of T-cells (d) was fixed at the reference value [24] . The resulting individual prediction goodness-of-fit plots for viral load and CD4 cell count are shown in Fig. 4 . Relative standard errors could not be calculated for the limited CD4? cell results, because of high variability. Despite this limitation, the viral load dynamic model described the time course of measured HIV-1 RNA data with reasonable fidelity, as indicated by the individual prediction plot (see Supplementary Fig. 5 in the Electronic Supplementary Material). Moreover, the estimated parameter values are generally comparable to those reported in several other studies as shown in Table 2 . Results of the independent compartment model describing LPV f pharmacokinetics were used as parameter input for developing the HIV viral dynamic model presented in Table 3 .
HIV-1 Dynamic Model
Simulated Exposure-Response Model
Based on the viral dynamic model simulation, the AAUCMB and C f12h values with LPV dosages ranging from 5 to 700 mg twice daily were obtained. The plot of the decrease in the AAUCMB vs C f12h is shown in Fig. 5a .
A sigmoid E max model successfully described the decrease in the AAUCMB relative to C f12h (exposure-response). The estimated E max was a decrease in the AAUCMB of 5.28 log 10 copies/mL, c was 0.899, and the EC 50 for C f12h was 0.227 ng/mL. The calculated EC 90 and EC 95 for C f12h were 2.61 and 6.00 ng/mL, respectively. Figure 5b depicts the decrease in AAUCMB vs C t12h . The estimated (range) EC 50 , EC 90 and EC 95 for C t12h at the median AAG concentration were 27.5 (25.1-58.3), 316 (289-672) and 726 (664-1542) ng/mL, respectively. The median LPV f and LPV t concentrations (interquartile range) at 12 h post-dose at steady state were 368 (23.4-547) and 5,327 (3, 157 ) ng/mL, respectively. Table 2 is 0.325 h -1 , which is also within the previously reported range of 0.267-0.564 h -1 [5, 26] . While there have been no previously reported compartmental models for LPV f pharmacokinetics on which to base a comparison of the results of our model presented in Table 2 , several published studies have reported AUC values for LPV f following therapy with LPV/RTV. The estimated AUC 0-12h obtained via simulation from our model is 414 ngÁh/mL, while Boffito et al. [30] reported an AUC 0-12h result of 890.14 ngÁh/mL, considerably higher than our result. However, this difference could be attributable to the different unbound fractions between the two studies: 0.73 vs 0.92 % (current studies). The differences in the unbound fraction may itself be due to the differences in AAG ranges observed across patients in the two studies: 58-116 vs 23.6-479 mg/dL in the current studies. Of note, our studies enrolled treatment-naïve patients with advanced disease as evidenced by a baseline median CD4? T-cell count of 69 cells/lL. HIV-1-induced immune activation up-regulates AAG synthesis. Conversely, down-regulation Fig. 3 Prediction-corrected visual predictive check of the combined total lopinavir/ ritonavir (LPV t /RTV) model (a) and free lopinavir (LPV f ) (b). The middle solid line is the median, the dashed lines are the 5th and 95th percentiles of the observed data and the shaded areas are the corresponding 95 % confidence intervals of the simulated data Fig. 4 Goodness of fit of individual prediction plots for the viral load (a) and the CD4 cell count (b). The symbols are the observed data, the red line is the linear regression, the black line is the line of unity and the dashed line is the upper limit of HIV-1 RNA quantitation [2, 31] . Thus participants in our studies likely had higher baseline AAG concentrations due to their advanced disease and treatment-naïve status. Methodological differences may have also played a role in the different free AUC 0-12h results, as our studies employed equilibrium dialysis compared with ultrafiltration.
AAG-Dependent LPV f Model
An independent population analysis was performed to develop a model relating measured LPV t and AAG concentrations to LPV f concentrations (see Table 2 ; Fig. 4 ). A linear model (see Eq. 5) best described the individual data over the AAG range of our studies. The data and modelling results presented herein suggest that variations in AAG concentrations could result in clinically significant changes in LPV pharmacokinetics. The model predicts that over the range of AAG values across the two studies there is a significant effect of AAG on LPV binding, with fu ranging from 0.00903 to 0.00389 (a 2.3-fold difference). Using the AAG-dependent LPV f model, the LPV f exposure changes can be predicted from AAG and C LPV t measurements.
HIV-1 Dynamic Model
In this work, we established a viral dynamic model to describe the viral load trajectory based on LPV f plasma concentration. This is the first analysis utilizing LPV f concentrations as the drug exposure metric linked to a HIV-1 viral dynamic model. The estimated drug efficiency and other viral dynamic parameters obtained in this study are in general agreement with other values reported in the literature as indicated in Table 2 , with the exception of the death rate of infected CD4? T-cells, which is smaller than the lowest value previously reported. The model estimated LPV f EC 50 is 5.84 ng/mL, which is consistent with the prescribing information for Kaletra from the US Food and Drug Administration [6] that indicates a range of LPV f concentrations of 3-7 ng/mL against several HIV-1 subtype B clinical isolates. In the presence of 50 % human serum, the mean EC 50 of LPV against five laboratory strains ranged from 40-180 ng/mL.
Simulated Exposure-Response Model
The median (interquartile range) of the observed LPV C t12h at 400 mg (with 100 mg RTV) is 5,327 (3,870-8,157) ng/mL. In contrast, the estimated C t12h required to achieve the EC 95 was 726 (664-1,542) ng/mL at the median (range) AAG concentration in these two studies of 91.8 (23.6-479) mg/dL. Figure 5 depicts the simulated exposure-response relationship for LPV f (a) and LPV t (b). Despite the wide range of AAG results, the 25th percentile of the observed C t12h (3,870 ng/mL) was considerably greater than the modelled EC 95 of LPV t ; even the 5th percentile of the observed C t12h (1,909 ng/mL) was 2.6 times greater than the EC 95 of LPV t . The simulated LPV t EC 50 was 27.5 ng/mL, which is lower than but relatively close to the range stated against different laboratory strains with 50 % human serum and nearly identical to the protein binding-corrected EC 50 (31 ng/mL) derived from a separate in vitro susceptibility study [32] .
Conclusions and Clinical Implications
Collectively, these modelling and simulation results demonstrate in part why LPV/RTV is a highly effective PI Fig. 5 Relationship between 12 h steady-state concentrations of free lopinavir (C f12h ) (a), total lopinavir (C t12h ) (b) and exposure [expressed as a decrease in the area under the viral load-time curve minus baseline (AAUCMB)] at day 7. The symbols and the solid red curve in a are the predicted C f12h and the sigmoid maximum response (E max ) fitted line, respectively. The C t12h was calculated by Eq. (5) with C f12h and a-1-acid glycoprotein (AAG). The solid red curve and the shaded orange area around the curve corresponds to the median (range) AAG of 91.8 (23.6-479) mg/dL in b. The dashed green line, solid purple line and shaded blue area are the estimated 95 % of the maximum response (EC 95 ), the observed median and the interquartile range of C f12h and C t12h at lopinavir/ritonavir 400/100 mg, respectively treatment regimen. As seen in Fig. 5 , observed trough concentrations consistently exceed, by a large margin, the concentrations required to durably suppress HIV-1 replication in vivo. This creates some flexibility for patients receiving the drug, as deviations from a strict 12-hourly dosing schedule are unlikely to significantly affect clinically outcomes. Importantly, this modelling and simulation approach could serve as a surrogate for determining clinically significant target drug exposures that must be achieved and maintained for durable therapeutic success and to prevent drug resistant viral strains. Concentrationresponse relationships for many ARVs are scarce or nonexistent. Our approach demonstrates that even for an ARV drug (particularly PIs) already approved for use at a fixed dose, it is possible to model and simulate minimum effective trough concentrations using data collected from well-designed clinical trials in a relatively small number of participants.
